WO2007005951A3 - Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders - Google Patents

Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders Download PDF

Info

Publication number
WO2007005951A3
WO2007005951A3 PCT/US2006/026166 US2006026166W WO2007005951A3 WO 2007005951 A3 WO2007005951 A3 WO 2007005951A3 US 2006026166 W US2006026166 W US 2006026166W WO 2007005951 A3 WO2007005951 A3 WO 2007005951A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
nervous system
central nervous
stereoisomeric
pyridonyl
Prior art date
Application number
PCT/US2006/026166
Other languages
French (fr)
Other versions
WO2007005951A2 (en
Inventor
Pascal Druzgala
Original Assignee
Aryx Therapeutics
Pascal Druzgala
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aryx Therapeutics, Pascal Druzgala filed Critical Aryx Therapeutics
Priority to EP06774511A priority Critical patent/EP1907376A2/en
Priority to MX2007016373A priority patent/MX2007016373A/en
Priority to JP2008520356A priority patent/JP2009500419A/en
Priority to CA002612893A priority patent/CA2612893A1/en
Publication of WO2007005951A2 publication Critical patent/WO2007005951A2/en
Publication of WO2007005951A3 publication Critical patent/WO2007005951A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The subject invention provides stereoisomeric compounds of formulae (Xa) and (Xb); wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.
PCT/US2006/026166 2005-07-05 2006-07-05 Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders WO2007005951A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06774511A EP1907376A2 (en) 2005-07-05 2006-07-05 Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders
MX2007016373A MX2007016373A (en) 2005-07-05 2006-07-05 Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders.
JP2008520356A JP2009500419A (en) 2005-07-05 2006-07-05 Stereoisomeric pyridyl and pyridonyl compounds and methods for treating gastrointestinal disorders and central nervous system disorders
CA002612893A CA2612893A1 (en) 2005-07-05 2006-07-05 Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69666205P 2005-07-05 2005-07-05
US60/696,662 2005-07-05

Publications (2)

Publication Number Publication Date
WO2007005951A2 WO2007005951A2 (en) 2007-01-11
WO2007005951A3 true WO2007005951A3 (en) 2007-03-29

Family

ID=37463520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/026166 WO2007005951A2 (en) 2005-07-05 2006-07-05 Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Country Status (6)

Country Link
EP (1) EP1907376A2 (en)
JP (1) JP2009500419A (en)
CN (1) CN101258145A (en)
CA (1) CA2612893A1 (en)
MX (1) MX2007016373A (en)
WO (1) WO2007005951A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138204B2 (en) 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CA2705947C (en) 2007-11-16 2016-08-09 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
JP5650540B2 (en) 2007-12-12 2015-01-07 ライジェル ファーマシューティカルズ， インコーポレイテッド Carboxamide, sulfonamide, and amine compounds for metabolic disorders
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1325921A2 (en) * 2002-01-07 2003-07-09 Pfizer Inc. Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
JP2005082508A (en) * 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd 2-alkoxy-6-amino-5-halogeno-n-(1-substituted-4-piperidinyl)pyridine-3-carboxamide derivative and pharmaceutical composition containing the same
JP2005104896A (en) * 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd 2-alkoxy-6-amino-5-halogenopyridine-3-carboxamide derivative and pharmaceutical composition containing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1325921A2 (en) * 2002-01-07 2003-07-09 Pfizer Inc. Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
JP2005082508A (en) * 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd 2-alkoxy-6-amino-5-halogeno-n-(1-substituted-4-piperidinyl)pyridine-3-carboxamide derivative and pharmaceutical composition containing the same
JP2005104896A (en) * 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd 2-alkoxy-6-amino-5-halogenopyridine-3-carboxamide derivative and pharmaceutical composition containing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200528, Derwent World Patents Index; AN 2005-266711, XP002411553 *
DATABASE WPI Week 200532, Derwent World Patents Index; AN 2005-310715, XP002411554 *

Also Published As

Publication number Publication date
CA2612893A1 (en) 2007-01-11
MX2007016373A (en) 2008-04-29
EP1907376A2 (en) 2008-04-09
WO2007005951A2 (en) 2007-01-11
CN101258145A (en) 2008-09-03
JP2009500419A (en) 2009-01-08

Similar Documents

Publication Publication Date Title
IL176569A0 (en) Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2007005951A3 (en) Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2007028073A3 (en) Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2007117381A3 (en) 2 -aminopyridine analogs as glucokinase activators
ZA200802163B (en) 5-(phenylisoxazolylethoxy)-triazol-3-YL substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders
WO2006133391A3 (en) Improved treatment for anemia using a hif-alpha stabilising agent
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
GB2442915B (en) Perylenequinone derivatives and uses thereof
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2008084223A3 (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
EP1817311A4 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
PL1900362T3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
TNSN07165A1 (en) Organic compounds
EP1814535A4 (en) Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
WO2005077902A3 (en) Methods for the synthesis of pyridoxamine
HK1155664A1 (en) Treatment of metastasized tumors
WO2008104590A3 (en) Novel dosage form
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2006089286A3 (en) Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2007079141A3 (en) Method of identifying compounds useful to treat neuronal degenerative diseases
WO2007013936A3 (en) Method for treating nervous system disorders and conditions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680032211.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/016373

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2612893

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008520356

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006774511

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE